+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometrial Cancer Treatment: Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309467

Quick Summary:

In the rapidly evolving landscape of healthcare, the global market for Endometrial Cancer Treatment is witnessing steady growth. Our detailed market research report presents an in-depth exploration of this thriving market's size, projected to reach $41.6 billion by 2030 from $28.3 billion in 2022. It specifically notes the growth potential of segments like Chemotherapy, poised to touch $28.2 billion by the close of this period.

This report also provides a well-rounded market overview inclusive of diverse geographic segments. The U.S. is firmly leading the charge with an estimate of $8.5 billion in 2022, but China closely follows with its own forecast of $7.4 billion by 2030. Key markets like Germany, Japan, and Canada also present strong growth outlooks. The analysis further includes data on market leaders like Abbott Laboratories, Sanofi SA, and Siemens Healthineers. Alongside comprehensive market coverage, the report offers special insights on impactful global events, competitive market shares, as well as archived research and bespoke updates for a comprehensive understanding of this booming marketplace.

Global Endometrial Cancer Treatment Market to Reach $41.6 Billion by 2030

The global market for Endometrial Cancer Treatment estimated at US$28.3 Billion in the year 2022, is projected to reach a revised size of US$41.6 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2022-2030. Chemotherapy, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$28.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hormone therapy segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.5 Billion, While China is Forecast to Grow at 4.8% CAGR

The Endometrial Cancer Treatment market in the U.S. is estimated at US$8.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Select Competitors (Total 38 Featured) -

  • Abbott Laboratories, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Siemens Healthineers

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Endometrial Cancer Treatment

What is the estimated value of the Global Market for Endometrial Cancer Treatment?

The Global Market for Endometrial Cancer Treatment was estimated to be valued at $28.3 Billion in 2022.

What is the growth rate of the Global Market for Endometrial Cancer Treatment?

The growth rate of the Global Market for Endometrial Cancer Treatment is 4.9%, with an estimated value of $41.6 Billion by 2030.

What is the forecasted size of the Global Market for Endometrial Cancer Treatment?

The Global Market for Endometrial Cancer Treatment is estimated to be worth $41.6 Billion by 2030.

Who are the key companies in the Global Market for Endometrial Cancer Treatment?

Key companies in the Global Market for Endometrial Cancer Treatment include Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Sanofi SA and Siemens Healthineers.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Endometrial Cancer Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Endometrial Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 11: USA Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 12: USA Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: USA 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
CANADA
  • Table 14: Canada Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 15: Canada Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: Canada 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
JAPAN
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 17: Japan Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: Japan Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: Japan 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
CHINA
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 20: China Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: China Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: China 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
EUROPE
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 23: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: Europe Historic Review for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Europe 16-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 26: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
FRANCE
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 29: France Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: France Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: France 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
GERMANY
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 32: Germany Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Germany Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Germany 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
ITALY
  • Table 35: Italy Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Italy Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Italy 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 38: UK Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: UK Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: UK 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 41: Rest of Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Rest of Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Rest of Europe 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Asia-Pacific Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Asia-Pacific 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
REST OF WORLD
  • Table 47: Rest of World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Rest of World Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Rest of World 16-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Siemens Healthineers